Top Industry Leaders in the Buergers Disease Market
Latest Buerger’s disease Companies Updates:
Jan 2024
STEMPEUTICS RESEARCH PVT LTD Received renewed approval from the Indian regulatory authorities for the commercialization of their Stempeucel, a stem cell-based therapy for BD.Conducted clinical trials on Stempeucel's efficacy and safety in BD patients, with promising results showing improved blood flow and pain relief.
t2cure GmbH Completed Phase II clinical trials for their novel anti-platelet aggregation drug candidate for BD, demonstrating positive effects on limb perfusion and symptom improvement.Partnered with academic institutions to investigate the underlying mechanisms of BD and identify potential new therapeutic targets.
Fujifilm Holdings Corporation Introduced their latest angiography system with improved image resolution and faster scan times, facilitating accurate diagnosis of vascular blockages associated with BD.Collaborated with healthcare providers to implement their system in BD diagnosis and treatment protocols.
Shimadzu Corporation Developed a portable non-invasive vascular assessment device for early detection of peripheral arterial disease, a major risk factor for BD.Focused on expanding their product portfolio for early diagnosis and monitoring of BD progression.
The Buerger's Disease Foundation Launched a new awareness campaign highlighting the early symptoms and importance of timely diagnosis for managing BD effectively.Funded research grants for BD research and patient advocacy initiatives.
List of Buerger’s disease Key companies in the market
- FUJIFILM Holdings Corporation (Japan)
- General Electric Company (US)
- Koninklijke Philips N.V. (the Netherlands)
- Pluristem (Israel)
- Shimadzu Corporation (Japan)
- Siemens Healthcare GmbH (Germany)
- STEMPEUTICS RESEARCH PVT LTD (India)
- Toshiba Medical Corporation (Japan)
- t2cure GmbH (Germany)
